Uttarakhand approves license for Coronil tablet to be used as supporting the measure in Covid-19 management. However, the State Licensing Authority of Uttarakhand says Coronil to be used without claiming cure. Also, it should follow the advice of a review committee set up by the AYUSH ministry.
The State Minister for Health Bharati Pravin Pawar said that the Interdisciplinary Technical Review Committee (ITRC) set up by the AYUSH ministry reviewed the application submitted by the Patanjali Research Foundation Trust for “updating the AYUSH license for Divya Coronil tablet” from ‘immunity booster’ to ‘medicine for COVID-19’.
Moreover, the committee suggested that the tablet may use as a supporting measure in Covid management, she said.
Also Read: ICMR Fourth Sero Survey Says – 67% Surveyed Indians Have Developed Covid-19 Antibodies
Pawar said in her reply that “The application titled ‘Updating AYUSH license for Divya Coronil tablet from Immunity booster to Medicine for Covid-19’ submitted by Patanjali Research Foundation Trust, Haridwar, Uttarakhand to this Ministry, was placed before the ITRC on October 27, 2020, for examination of the applications/claims on patent and propriety (P&P) ASU&H medicines with new indications or repurposing of licensed P&P, ASU&H medicines for Covid-19.”
She also added to her statement “The ITRC reviewed the study and it was suggested that it may be used as a supporting measure in Covid. The State Licensing Authority was also informed that the Coronil tablet may be used as a supporting measure in the management of Covid-19 without claiming cure.”
She said that the approval granted under the regulatory provisions for granting approval and license of Ayurvedic, Siddha, Unani, and Homoeopathy drugs prescribed under the Drugs and Cosmetics Act, 1940 and Rules 1945.
